Dementia Drugs, Treatments and Trials
Treatments for dementia still vary widely by country. Wealthier health systems in the United States and parts of Europe can offer licensed disease-modifying drugs, while many lower income regions still rely on community support, risk factor control and family care. The newer medicines aim to slow Alzheimer’s disease itself, not only ease symptoms. That is a real shift, but access remains uneven and no treatment is a cure.
Dementia Hub looks at current options in the UK and worldwide, and at the drugs now in trials and when they might reach the public.
Early diagnosis still matters more than ever. Assessment usually starts with memory tests, a medical history and blood work to rule out other causes, then brain scans or specialist tests if needed. Blood tests that pick up Alzheimer’s proteins such as p-tau217 are now widely used in research and some private clinics. On the NHS they are still being trialled, with the Blood Biomarker Challenge aiming for routine use by around 2029. Support for carers remains essential, because dementia changes family life as well as the person diagnosed. Charities such as Alzheimer’s Society can offer advice through helplines, dementia cafés and local groups.
Living well with dementia still rests on familiar foundations: staying active, eating well, sleeping properly and keeping social ties. Memory aids, routines and activity groups can make daily life easier. Research funding has grown in several countries, with more money going into prevention and disease modifying treatments rather than symptom care alone. In England the estimated diagnosis rate for people aged 65 and over is still only about 66 per cent, short of the two thirds target and well below what is needed if new drugs are to be used in time. Where we can, we use plain language for complex science.
Current Drugs and Treatments in the UK
UK care still centres on managing symptoms and supporting daily life. The NHS treats most people. Private clinics can offer faster assessment and, for those who can pay, the new anti amyloid drugs.
NHS Treatments
The NHS provides treatment according to need. There is no cure, but licensed drugs and therapies can help.
Symptom Managing Drugs
Four main symptom drugs remain approved:
- Donepezil (Aricept): used for mild to severe Alzheimer’s. It raises acetylcholine, a chemical that helps brain cells communicate. It is taken as a tablet once a day. Feeling sick or tired is common at first, but this often fades.
- Rivastigmine (Exelon): used for mild to moderate Alzheimer’s and for dementia with Lewy bodies. It comes as tablets, liquid or a skin patch. Patches can help people who forget tablets. Side effects include an upset stomach or skin irritation from the patch.
- Galantamine (Reminyl): used for mild to moderate Alzheimer’s. It also boosts acetylcholine and is available as tablets or liquid. Side effects are similar to donepezil.
- Memantine (Ebixa or other brands): used for moderate to severe Alzheimer’s, or when the first three drugs are not suitable. It dampens excess glutamate, which can damage brain cells. It is taken as tablets. Headache or dizziness can occur.
These medicines do not stop dementia. They can steady thinking and daily function for some people for months, sometimes longer. Specialists usually start them after assessment. For vascular dementia the priority is treating blood pressure, cholesterol and other vascular risks, often with medicines such as ACE inhibitors or statins.
For severe agitation, antipsychotics such as risperidone or haloperidol may be used for a short time under strict rules. They are reserved for the most difficult cases and reviewed often because of risks including stroke.
Lecanemab (Leqembi) and donanemab (Kisunla) are the first UK licensed drugs shown to slow early Alzheimer’s by clearing amyloid plaques. The MHRA licensed lecanemab in August 2024 and donanemab in October 2024. Trials found lecanemab slowed decline by about 27 per cent and donanemab by about 35 per cent in selected people with early disease and confirmed amyloid. NICE has repeatedly judged that the benefit is too modest, and the cost of the drugs plus infusions, genetic testing and MRI monitoring too high, for routine NHS use. As of September 2026 neither is recommended on the NHS. NICE, NHS England and the manufacturers have been in commercial talks since July 2026, but no funding decision has been announced.
Non Drug Options
The NHS also offers therapies with good evidence in mild disease:
- Cognitive Stimulation Therapy (CST): group sessions with discussion, puzzles and activities, usually twice a week for several weeks.
- Cognitive training: structured practice on paper, computers or apps.
- Cognitive rehabilitation: working with a therapist on personal goals, such as managing cooking or appointments.
- Reminiscence therapy: using photos, music or familiar objects to support mood and conversation.
Occupational therapy, physiotherapy and speech and language therapy can help at home. The NHS can also fund care home places when needs are high.
Access usually starts with a GP referral to a memory clinic. Diagnosis rates in England have risen slowly and were about 66 per cent in mid 2026 but waiting times from referral to diagnosis remain long in many areas.
The government’s 10 Year Health Plan and the Dame Barbara Windsor Dementia Goals programme both promise faster diagnosis, better trial recruitment and stronger carer support. Blood biomarker studies in memory clinics and GP practices are part of that effort.
Private Treatments
Private clinics offer the same symptom drugs with shorter waits for scans and specialists. Consultations often cost a few hundred pounds, with medicines extra. Centres such as Re:Cognition Health, Dementech and some hospital private wings can also prescribe lecanemab and donanemab to eligible patients who pay.
Lecanemab is given as a hospital infusion every two weeks at first. In the United States a weekly home injection is now licensed for starting and maintenance treatment; UK regulators are still considering that option. Donanemab is usually given monthly and can sometimes be stopped once scans show amyloid has been cleared. Both need APOE genetic testing and regular MRI scans because of amyloid related imaging abnormalities (ARIA), which can cause brain swelling or small bleeds. Private packages, including monitoring, commonly run to tens of thousands of pounds a year.
Some private services also offer extra therapies such as transcranial magnetic stimulation. These are not standard NHS treatments. Homecare packages can be tailored, but insurers often exclude the new antibodies.
Private diagnosis can take weeks rather than many months. That speed is the main advantage. Cost remains the barrier.
Comparing NHS and Private
The NHS is free at the point of use but slower, and it does not yet fund the anti-amyloid drugs. Private care is faster and can offer those drugs, at high cost. Both use MHRA approved medicines. Support groups and research networks can help people find trials. Alzheimer’s Society still runs dementia cafés across the country.
Dementia Drugs and Treatments Worldwide
Richer countries generally have more licensed options and stronger diagnostic services. Poorer countries still lean on family care, education and treatment of high blood pressure, diabetes and other risks.
United States
The US has moved fastest on new drugs. The FDA approved lecanemab (Leqembi) in 2023 and donanemab (Kisunla) in 2024. In 2025 and 2026 it also approved less frequent intravenous maintenance dosing for lecanemab, then a weekly under the skin autoinjector for maintenance and, in July 2026, for starting treatment. That makes home dosing possible for the whole course. Donanemab remains a monthly infusion and can be stopped after amyloid clearance.
Medicare covers both antibodies for eligible people with confirmed amyloid. List prices are still high, often more than $26,000 a year for the medicine alone before administration and scans. The older symptom drugs, including the combination Namzaric (memantine plus donepezil), remain widely used.
More than seven million Americans aged 65 and over now live with Alzheimer’s dementia. National Institutes of Health funding for trials remains large.
Europe and the EU
The European Medicines Agency approved lecanemab in April 2025 and donanemab in September 2025, but only for people who are not APOE4 homozygotes and who have confirmed amyloid. Reimbursement is another matter. Health technology bodies in the UK, France, Spain, Sweden, Denmark, Finland and the Netherlands have so far declined routine public funding. Germany has allowed some hospital use, but its benefit assessment found little added value over standard care, which makes long term reimbursement harder. Austria and Luxembourg have offered limited early coverage.
France has focused on home care and has rejected reimbursement for both antibodies. Scandinavia still has high diagnosis rates and strong social care, with tools such as GPS trackers used in Norway. Access to the new drugs is slower than in the US mainly because of cost and service capacity, not because regulators doubt that the drugs clear amyloid.
Asia
Japan helped develop lecanemab with Eisai and approved it in 2023. It is in wider use there than in most of Europe. China approved lecanemab in 2024 and later approved maintenance dosing. Traditional products such as ginkgo are still used alongside licensed medicines. China has more than 10 million people with dementia and still relies heavily on family care.
India offers the older drugs at low cost. Private clinics in large cities can provide newer options. Public health work still concentrates on prevention through diet, blood pressure and diabetes care.
Australia and Canada
Australia subsidises donepezil and the other symptom drugs through the PBS. Lecanemab has been approved, but high cost has limited public use. Canada’s system looks similar to the UK’s, with the new antibodies under review or restricted and extra attention on the needs of Indigenous communities.
Developing Countries
Across much of Africa and Latin America specialist anti amyloid treatment is rare. The practical focus is community support, education and control of vascular risk. Global hope around anti amyloid drugs is real, but prices above $20,000 a year and the need for MRI monitoring put them out of reach for most people. Repurposed medicines remain an important research route because they are cheaper to test.
Dementia Trial Phase Drugs
Dementia affects tens of millions of people and there is still no complete cure. Most drug development focuses on Alzheimer’s, the commonest cause. The 2026 pipeline review, using an index date of 1 January 2026, found 192 active Alzheimer’s trials of 158 unique drugs. That is up from 182 trials and 138 drugs in 2025.Phase 1 tests safety in small groups. Phase 2 tests whether a drug appears to work. Phase 3 tests it in large numbers before regulators decide. About a third of trials run across several continents. Industry funds most studies, with governments and charities filling gaps. More than 50,000 people are needed across the pipeline. About 35 per cent of the drugs are repurposed from other diseases, which can save time because safety is already partly known.
Trials now rely heavily on brain scans and blood tests to choose the right participants and to measure change. Targets include amyloid plaques, tau tangles, inflammation, synapses, metabolism and, increasingly, combinations of these. Eight Phase 3 trials were due to reach their main completion date in 2026, and 29 Phase 2 trials were due to finish.
Phase 3 Trials: Nearest to Market
Phase 3 now includes 54 trials of 36 drugs. These are the largest studies and last one to three years or more. Most still try to change the disease itself. Others aim to protect thinking or ease agitation and psychosis.Key programmes include:
- Lecanemab and donanemab: already licensed in several countries and still being tested in earlier, preclinical or combination studies.
- Trontinemab: Roche’s “brain shuttle” antibody, designed to get more drug into the brain at a lower dose. Large Phase 3 trials are recruiting, and a prevention study in people with raised p-tau217 but no symptoms has begun in the UK and elsewhere.
- Remternetug: Lilly’s next anti amyloid antibody, in Phase 3.AR1001 (mirodenafil): an oral drug in a large global Phase 3 study in early Alzheimer’s, with results expected from 2026.
- KarXT (xanomeline plus trospium): already licensed in the US for schizophrenia and being studied for psychosis in dementia.
- Nabilone and dextromethorphan quinidine: still explored for agitation.
Some earlier Phase 3 hopes have closed. Oral semaglutide did not slow clinical decline in the large evoke and evoke+ trials, even though some Alzheimer’s biomarkers improved. Simufilam failed two Phase 3 studies and development for Alzheimer’s was stopped. Aducanumab has been withdrawn.
Industry funds most Phase 3 work. If remaining studies succeed, further approvals are more likely from 2027 onwards than in 2026.
Phase 2 Trials: Gathering Proof
Phase 2 includes 89 trials of 84 drugs and about 13,000 to 14,000 participants. Four in five agents still target the disease process. Oral drugs are more common here than in Phase 3.
Examples include ALZ-801 (valiltramiprosate), an oral tablet aiming to stop amyloid from clumping; blarcamesine (Anavex); sabirnetug; etalanetug (anti-tau, often combined with lecanemab); BIIB080 / diranersen (tau lowering antisense therapy); and zervimesine (CT1812), now also being lined up for dementia with Lewy bodies psychosis.
Repurposed drugs make up a large share of Phase 2. Many studies last about a year. Results due through 2026 will decide which agents move into Phase 3.
Phase 1 Trials: First Safety Checks
Phase 1 includes 49 trials of 45 drugs and a few thousand people. Most agents still attack disease biology: plaques, tau, receptors or inflammation. Studies are shorter and often based in North America. Growth at this stage shows new ideas are still entering the pipeline.
Reused Drugs and Global Reach
Fifty-six drugs in the 2026 pipeline are repurposed, about 35 per cent of the total. They come from diabetes, cancer, psychiatry and other fields. Semaglutide’s failed Alzheimer’s trials show that a known safety record is not enough. Biomarker change does not always mean people think or function better.
Trials run at thousands of sites. Phase 3 is the most global. North America still leads, but Europe and Asia are taking a larger share. Prevention studies in people with no symptoms but abnormal blood or scan results are growing, though they remain a small part of the pipeline.
New Trends and Hopes
Blood tests for amyloid and tau now guide who enters many trials and how success is judged. Combination treatment is rising: anti-amyloid drugs plus anti-tau, anti-inflammatory or metabolic agents. Oral and subcutaneous options are a clear trend because fortnightly hospital infusions are hard to scale.
Targets have widened. Amyloid now accounts for about a fifth of the pipeline, down from a third a decade ago. Inflammation, tau and synaptic repair have grown. The main constraints are cost, ARIA and the simple fact that slowing decline by a few months may not look worthwhile to health services. Even so, the pipeline is broader than it was in 2024 or 2025.
New drugs and trials are paid for from three sources: public money, company investment and charity donations. Public funders support long term science and NHS ready trials. Companies pay for the most expensive late stage studies because they hope to sell a licensed medicine. Charities often back early ideas and independent trials.
Public Funding for Dementia Research
The Medical Research Council remains the main public backer of discovery science. It created the UK Dementia Research Institute in 2017 and remains its core funder. The institute now works across nine centres and lists more than 1,000 scientists. The MRC has also put fresh money into experimental medicine, including about £16.5 million announced in late 2025 for studies that test mechanisms of neurodegeneration in people.
The National Institute for Health and Care Research funds trials in the NHS and has pledged up to £50 million for a UK Dementia Trials Network. A further £20 million from the MRC supports the Dementia Trials Accelerator, run with Health Data Research UK and the UK DRI, to find and enrol thousands of volunteers much faster than before.
The Dame Barbara Windsor Dementia Goals programme, launched in 2022, aligns up to £150 million across biomarkers, trials and implementation. In 2026 it also helped launch BARBARA, a national “virtual registry” that links existing research databases so companies and academics can find trial volunteers more quickly.
Innovate UK and other agencies continue to fund biomarker and diagnostics projects. Public money also supports vascular dementia work with partners such as the British Heart Foundation. The aim is a stable base that industry and charities cannot provide alone.
Private Funding for Dementia Research
Eli Lilly, Eisai, Biogen, Roche, Novo Nordisk and others still fund the largest trials. Lilly and Eisai paid for the studies that led to donanemab and lecanemab. Roche is putting major investment behind trontinemab. Companies sometimes supply free drug or grants to independent investigators.
Venture funds and groups such as the Dementia Consortium still back early projects, often up to about £1 million. LifeArc has committed £30 million to translational work at the UK DRI. Gates Ventures and Alzheimer’s Research UK have continued the Dementia Frontiers Fund to clear bottlenecks in discovery. Private money is what usually carries a drug through Phase 3.
Charity Funding
Alzheimer’s Research UK remains one of the largest charity funders, with tens of millions of pounds across discovery, biomarkers and the Global Clinical Trials Fund. Alzheimer’s Society funds project grants, fellowships and care research, and is a founding funder of the UK DRI. In 2026 it opened a large strategic call for non Alzheimer’s dementias.
Race Against Dementia still offers substantial fellowships. Parkinson’s UK has invested in UK DRI work on overlapping conditions. Charity funding often supports ideas that are too early or too independent for companies, and it helps the public take part in research.
Creating Dementia Drugs
The UK DRI alone now involves more than 1,000 scientists across its centres. Alzheimer’s Research UK and Alzheimer’s Society support hundreds more through grants. Add academic groups, NHS trial teams and UK staff in pharmaceutical companies, and the domestic research community is well over that figure. Exact headcounts change with grants, but the field is larger than it was when the institute opened in 2017.
These funding streams work best together. Public and charity money build the science and the trial platforms. Industry pays to take a successful idea through regulation.
Dementia Drugs Summary
As of the 2026 pipeline review there are 192 Alzheimer’s trials of 158 drugs, up from 182 trials and 138 drugs the year before. Most still target plaques, tau, inflammation or weak synapses. More than 50,000 participants are needed across the studies. About 35 per cent of agents are repurposed.
Phase 3 (54 trials, 36 drugs): closest to patients. Licensed anti amyloid drugs are being refined and tested earlier in the disease. Trontinemab, remternetug and oral AR1001 are among the programmes to watch. Semaglutide and simufilam have already failed their main Alzheimer’s trials.
Phase 2 (89 trials, 84 drugs): where most new ideas are tested. Oral anti-amyloid and anti-tau approaches, synaptic drugs and several combination studies sit here.
Phase 1 (49 trials, 45 drugs): safety and first signals. New targets, including gut brain and immune pathways, appear first at this stage.
Prevention trials in people with abnormal blood tests but no symptoms are growing. So are oral and home injectable options. The limits are familiar: cost, side effects such as ARIA, and modest clinical benefit. The more honest hope is not a sudden cure by 2030, but a wider set of treatments that slow decline for some people, started earlier, with simpler tests and fewer hospital visits.
Case numbers are still rising. That is why faster diagnosis and better trials matter. Today’s symptom drugs can ease daily life. The newer antibodies can slow early Alzheimer’s a little for selected patients. The next wave will only help if health systems can identify people early enough, and if prices and monitoring become realistic for public care. Lifestyle changes and prompt action on memory concerns remain the steps anyone can take now.
Factcheck 07/09/2026
Grok (X): The article is highly accurate as of 7 September 2026. Core UK, US, EU, pipeline and funding claims check out; only a few figures are slightly rounded but the information is valid.
Google AI: The Dementia Hub article is highly accurate, precisely aligning with 2026 data. It correctly states standard NHS symptom drugs, the rejection of public funding for lecanemab and donanemab, and accurately cites the exact figures from the 2026 Alzheimer's pipeline study (158 drugs across 192 trials).
Dementia Hub: This page has been verified accurate via the above AI engines, we recommend consulting a fully trained health official before making any changes to your diet, medication or routine.